AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Kairos Pharma Soars 17.04% on Positive Trial Data
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Sep 2, 2025 4:56 am ET1min read
Aime SummaryOn September 2, 2025, Kairos Pharma's stock surged by 17.04% in pre-market trading, marking a significant rise in investor interest and confidence in the company's prospects.
Kairos Pharma is gearing up for a pivotal month in September 2025, as the company is set to report interim efficacy data from its Phase 2 trial of ENV-105. This trial is focused on patients with metastatic castration-resistant prostate cancer, a form of advanced prostate cancer. The interim safety analysis of the trial has already shown that ENV-105 is well tolerated when combined with standard-of-care hormone therapy, Apalutamide, with no dose-limiting toxicities or unexpected adverse events reported to date.
The positive safety results and the upcoming efficacy data release have positioned
as a key player in the biotech sector, with investors closely monitoring the company's progress. The successful outcome of the Phase 2 trial could pave the way for further development and potential approval of ENV-105, offering a new treatment option for patients with advanced prostate cancer.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
United States Antimony (UAMY) Surges 5.31% on Year-End Portfolio Adjustments by Institutional Investors
Dec.26 2025
Strive Asset Management (NASDAQ:ASST) surges 7.03% on strategic dividend adjustment to 12.25% from 12%
Dec.26 2025
Sweetgreen (NYSE:SG) surges 5.41% on strategic expansion and new Sacramento locations
Dec.26 2025
Autozi Internet shares surge 13.54% on strategic initiatives and autonomous vehicle developments
Dec.26 2025
Strive surges 7.03% as delisting concerns and dividend boost drive buying
Dec.26 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet